Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Colorectal Cancer

Breast Cancer

Gastrointestinal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Colorectal Cancer

Pembrolizumab Improves PFS in Frontline MSI-H/dMMR Colorectal Cancer

Frontline pembrolizumab significantly improved progression-free survival versus chemotherapy in patients with microsatellite instability–high or mismatch repair deficient unresectable or metastatic colorectal cancer.

Read More >>

Marshall Reflects on Major Advances in mCRC

Management, Etiology of Younger Patients With CRC Require Deeper Understanding

TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC

Advancing the mCRC Paradigm With Clinical Trials and Molecular Profiling

Research in mCRC Underscores Importance of Individualized Approach

View More Stories >>

View Conference Coverage

2020 SGO Annual Meeting

2020 School of Gastrointestinal Oncology

2020 New York GU

2020 Miami Breast Cancer Conference

2020 HCC-TAG Conference

Dr. Raghav on Ongoing Research With Immunotherapy and Targeted Therapy in CRC

Dr. Overman on Choosing Between Regorafenib and TAS-102 in CRC

Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRC

Dr. Mizrahi on Optimal Sequencing in <em>BRAF</em> V600E-Mutant mCRC

Dr. Armaghany on the Importance of the NCI-MATCH Trial in CRC

Dr. Nelson on QOL Data From the BEACON CRC Trial in mCRC

Dr. Le on the Need for Aggressive Treatment Interventions in Oligometastatic CRC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Future Directions in I/O Therapy for mCRC

Immunotherapy in CRC

New Therapy Options for BRAF-Mutated mCRC

Management of Colorectal Cancer Metastases

TRIBE-2: FOLFOX or FOLFIRI With Bevacizumab in mCRC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Novel Therapeutic Targets and Combinations in mCRC

MCRC: Future Directions for Molecular-Driven Treatment

Future Directions for Later-Line Therapy in R/R mCRC

Role of Immunotherapy in Microsatellite-Stable R/R mCRC

$Relapsed/Refractory mCRC: Immunotherapy in MSI-High Tumors$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Treatment Goals in Refractory mCRC

$Treatment Goals in Refractory mCRC$
Tanios Bekaii-Saab, MD, FACP, Andrea Cercek, MD, and Zev A. Wainberg, MD, provide insight to the treatment goals for patients with refractory metastatic colorectal cancer.

View Now

Therapeutic Strategies in Metastatic Colorectal Cancer

Recent advances in the treatment of metastatic colorectal cancer (mCRC) have improved survival. However, many questions remain. Led by John L. Marshall, MD, panelists Tanios Bekaii-Saab, MD; Johanna Bendell, MD; Richard Kim, MD; and Charles S. Fuchs, MD, MPH, discuss strategies and approaches to managing mCRC, including the latest research and how it may influence clinical practice.

View Now

Featured Video

The Emerging Role of Chemotherapy in Metastatic Prostate Cancer